Cargando…

A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer

Trastuzumab resistance in HER2-positive breast cancer is associated with a poorer prognosis. HSP90 is thought to play a major role in such resistance, but N-terminal inhibitors of this target have had little success. We sought to investigate the utility of NCT-547, a novel, rationally-designed C-ter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jung Min, Kim, Yoon-Jae, Park, Soeun, Park, Minsu, Farrand, Lee, Nguyen, Cong-Truong, Ann, Jihyae, Nam, Gibeom, Park, Hyun-Ju, Lee, Jeewoo, Kim, Ji Young, Seo, Jae Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678296/ https://www.ncbi.nlm.nih.gov/pubmed/33218356 http://dx.doi.org/10.1186/s12943-020-01283-6

Ejemplares similares

The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells
por: Park, Soeun, et al.
Publicado: (2021)

A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
por: Kim, Ji Young, et al.
Publicado: (2022)

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
por: Park, Soeun, et al.
Publicado: (2022)

A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects
por: Lee, Ho Jin, et al.
Publicado: (2022)

Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer
por: Hyun, Seung Yeob, et al.
Publicado: (2018)

Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
por: Park, Sangkyu, et al.
Publicado: (2019)

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
por: Kim, Seongjae, et al.
Publicado: (2023)

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase
por: Seo, Juyeon, et al.
Publicado: (2023)

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
por: Park, Kang-Seo, et al.
Publicado: (2018)

Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1
por: Park, Hye-Kyung, et al.
Publicado: (2020)

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
por: Chandarlapaty, Sarat, et al.
Publicado: (2009)

Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance
por: Hwang, Soo-Yeon, et al.
Publicado: (2020)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus
por: Slotta-Huspenina, Julia, et al.
Publicado: (2014)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen
por: Kong, Anthony, et al.
Publicado: (2016)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
por: Lee, Hye Jin, et al.
Publicado: (2020)

Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using (89)Zr-DFO-Trastuzumab
por: Holland, Jason P., et al.
Publicado: (2010)

An Aminopropyl Carbazole Derivative Induces Neurogenesis by Increasing Final Cell Division in Neural Stem Cells
por: Shin, Jae-Yeon, et al.
Publicado: (2015)

Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain
por: Kim, Hyun-Hwi, et al.
Publicado: (2018)

Development of machine learning models for the screening of potential HSP90 inhibitors
por: Khan, Mohd Imran, et al.
Publicado: (2022)

Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas
por: Berezowska, Sabina, et al.
Publicado: (2013)

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
por: Lee, Ji Yun, et al.
Publicado: (2015)

Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis
por: Park, Joo-Hwan, et al.
Publicado: (2022)

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment
por: Kwon, Hyun Jung, et al.
Publicado: (2023)

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
por: Seo, An Na, et al.
Publicado: (2016)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Enhancing viability and angiogenic efficacy of mesenchymal stem cells via HSP90α and HSP27 regulation based on ROS stimulation for wound healing
por: Seo, Inwoo, et al.
Publicado: (2023)

Combination of a Rapidly Penetrating Agonist and a Slowly Penetrating Antagonist Affords Agonist Action of Limited Duration at the Cellular Level
por: Pearce, Larry V., et al.
Publicado: (2019)

Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells
por: Park, Sangkyu, et al.
Publicado: (2017)

HSP-90 Inhibitor Ganetespib is Synergistic with Doxorubicin in Small Cell Lung Cancer
por: Lai, Chien-Hao, et al.
Publicado: (2013)

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
por: Han, Hye-Suk, et al.
Publicado: (2009)

Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
por: Jeong, Hyehyun, et al.
Publicado: (2021)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Predicting Cyanobacterial Blooms Using Hyperspectral Images in a Regulated River
por: Ahn, Jung Min, et al.
Publicado: (2021)

Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg function
por: Collins, Colm B., et al.
Publicado: (2013)

Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non–Small Cell Lung Cancer
por: Yoon, Shinkyo, et al.
Publicado: (2022)

Hsp90 inhibition and co‐incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T‐DM1
por: Skeie, Marianne, et al.
Publicado: (2020)

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy
por: Jung, Minkyu, et al.
Publicado: (2012)

Functional Group-Dependent Induction of Astrocytogenesis and Neurogenesis by Flavone Derivatives
por: Lee, Ha-Rim, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c0ktoofutsu19aqufefpkohn9p